Roche agreed a broad ADC collaboration with Hansoh that includes $400 million upfront and up to $15 billion in biobucks. The deal underscores Roche’s continued push to expand its antibody-drug conjugate portfolio through China-focused partnerships. ADC programs often depend on platform technology for target selection, payload optimization, and manufacturing scale, and large cross-border agreements can compress timelines by aligning development responsibilities across geographies. For Hansoh, the partnership expands validation of its ADC pipeline approach and may provide additional capacity for later-stage progression and combination exploration. The announcement arrives as multiple large pharma players seek to widen their oncology ADC reach, balancing speed, manufacturing capability, and regulatory execution across markets.